Comparative efficacy and safety of lorlatinib and alectinib for ALK rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: systematic review and network meta-analysis.
Not Applicable
- Conditions
- non-small cell lung cacner
- Registration Number
- JPRN-UMIN000043994
- Lead Sponsor
- Showa University school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2194
Inclusion Criteria
Not provided
Exclusion Criteria
Studies for children Observational studies
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method